TABLE 5.

MIC distributions for β-lactams and ciprofloxacin against 100 clinical isolates of BLPACR H. influenzae

Antimicrobial agent(s)	No. of isolates with MIC (μg/ml):										MIC (μg/ml)			% of isolates susceptiblea
	≤0.12	0.25	0.5	1	2	4	8	16	32	≥64	Range	50%	90%
Ampicillin	0	0	0	0	0	0	100	—b	—	—	≥8	≥8	≥8	0
Ampicillin-sulbactam	0	0	0	0	0	0	89	11	0	0	8-16	8	16	0
Amoxicillin-clavulanate	0	0	0	0	0	0	96	4	0	0	8-16	8	8	0
Piperacillin	0	0	0	0	0	1	17	15	25	42	4-≥64	32	≥64
Piperacillin-tazobactam	74	24	2	0	0	0	0	0	0	0	≤0.03-0.5	0.12	0.25	100
Ceftriaxone	56	37	7	0	0	0	0	0	—	—	≤0.008-0.5	0.12	0.25	100
Imipenem	1	3	7	37	45	5	2	—	—	—	≤0.12-≥8	2	2	98
Meropenem	26	40	34	0	0	0	0	—	—	—	≤0.12-0.5	0.25	0.5	100
Ciprofloxacin	91	6	2	0	1	—	—	—	—	—	≤0.03-≥2	≤0.03	0.12	99

^aCLSI MIC breakpoints (5).

^b—, untested concentration.